29.11.2022 - NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) - BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, .